Clinical trial
Prospective, Multicenter, Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients as Per Routine Clinical Practice in Germany Depending on Application Route (sc or iv)
NCT05284591 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Multicenter, Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients as Per Routine Clinical Practice in Germany Depending on Application Route (sc or iv)
- Lead sponsor
- iOMEDICO AG
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 6, 2022
- Completion date
- September 20, 2024
- Enrollment
- 96 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
multiple myeloma, newly diagnosed, patient preference, patient satisfaction, personal satisfaction, transplant ineligible